PURPOSE: This retrospective study utilized a large, national hospital database to assess the impact of opioid-related adverse events (ORADE) on patient outcomes following selected surgical procedures known to require postoperative pain control. METHODS: Outcomes of patients with administratively documented ORADE were compared to those without. Multivariate regression determined differences in hospital costs; length of stay (LOS); odds of individuals being an outlier in total cost and LOS; and having a 30-day all-cause readmission. RESULTS: Among 319,898 surgeries of interest, 12.2% of patients experienced an ORADE. Patients had higher adjusted mean costs ($22,077 [95% CI 21,823-22,333] vs. $17,370 [95% CI 17,238-17,503]; p < 0.0001) and greater LOS (7.6 [95% CI 7.5-7.6] vs. 4.2 days [95% CI 4.2-4.2]; p <0.0001). Adjusted odds of being a total cost and LOS outlier were 2.8 (95% CI 2.7-2.8) and 3.2 (95% CI 3.1-3.3) times greater in the ORADE group. These patients were more likely to be readmitted (OR 1.06, 95% CI 1.02-1.09). CONCLUSIONS: Patients exhibiting a documented ORADE had greater overall costs, longer hospitalizations, and increased likelihood for readmission. These results highlight the economic impact associated with opioid use for postsurgical pain management.
PURPOSE: This retrospective study utilized a large, national hospital database to assess the impact of opioid-related adverse events (ORADE) on patient outcomes following selected surgical procedures known to require postoperative pain control. METHODS: Outcomes of patients with administratively documented ORADE were compared to those without. Multivariate regression determined differences in hospital costs; length of stay (LOS); odds of individuals being an outlier in total cost and LOS; and having a 30-day all-cause readmission. RESULTS: Among 319,898 surgeries of interest, 12.2% of patients experienced an ORADE. Patients had higher adjusted mean costs ($22,077 [95% CI 21,823-22,333] vs. $17,370 [95% CI 17,238-17,503]; p < 0.0001) and greater LOS (7.6 [95% CI 7.5-7.6] vs. 4.2 days [95% CI 4.2-4.2]; p <0.0001). Adjusted odds of being a total cost and LOS outlier were 2.8 (95% CI 2.7-2.8) and 3.2 (95% CI 3.1-3.3) times greater in the ORADE group. These patients were more likely to be readmitted (OR 1.06, 95% CI 1.02-1.09). CONCLUSIONS:Patients exhibiting a documented ORADE had greater overall costs, longer hospitalizations, and increased likelihood for readmission. These results highlight the economic impact associated with opioid use for postsurgical pain management.
Authors: Jennifer F Waljee; David C Cron; Rena M Steiger; Lin Zhong; Michael J Englesbe; Chad M Brummett Journal: Ann Surg Date: 2017-04 Impact factor: 12.969
Authors: Shahid Shafi; Ashley W Collinsworth; Laurel A Copeland; Gerald O Ogola; Taoran Qiu; Maria Kouznetsova; I-Chia Liao; Natalie Mears; An T Pham; George J Wan; Andrew L Masica Journal: JAMA Surg Date: 2018-08-01 Impact factor: 14.766
Authors: Elise A Dasinger; Westyn Branch-Elliman; Steven D Pizer; Hassen Abdulkerim; Amy K Rosen; Martin P Charns; Mary T Hawn; Kamal M F Itani; Hillary J Mull Journal: Am J Surg Date: 2019-01-04 Impact factor: 2.565
Authors: M Katherine Henry; Mark R Zonfrillo; Benjamin French; Lihai Song; Chris Feudtner; Joanne N Wood Journal: Acad Pediatr Date: 2016-02-04 Impact factor: 3.107
Authors: John W Barrington; Roger H Emerson; Scott T Lovald; Adolph V Lombardi; Keith R Berend Journal: Clin Orthop Relat Res Date: 2017-01 Impact factor: 4.176
Authors: Karim S Ladha; Elisabetta Patorno; Krista F Huybrechts; Jun Liu; James P Rathmell; Brian T Bateman Journal: Anesthesiology Date: 2016-04 Impact factor: 7.892